A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
Todd W. Rice(Vanderbilt University), Jon Cohen(University of Toronto), Gordon R. Bernard(Vanderbilt University Medical Center), Hideyasu Matsuda, Ignace Demeyer(Onze Lieve Vrouwziekenhuis Hospital), Stephen M. Sainati, Nicholas Amlot, Masayuki Ii, Arthur P. Wheeler(Bridge University), Charlie Cao, Naoki Aikawa, Derek C. Angus(University of Pittsburgh), Kouji Mouri, Jean‐Louis Vincent(Université Libre de Bruxelles)
Cited by 500
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k